Brian Daniels - 01 Jun 2021 Form 4/A - Amendment Insider Report for Cabaletta Bio, Inc. (CABA)

Reporting relationship: Director
Issuer ticker: CABA
Reported as of: 01 Jun 2021
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 28 Jun 2021, 16:30:24 UTC
Original report date: 03 Jun 2021
Next SEC filing: 18 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Steven Nichtberger, Attorney-in-Fact

Key filing fact

Brian Daniels filed Form 4/A - Amendment for Cabaletta Bio, Inc. (CABA) on 28 Jun 2021.

Key facts

This page summarizes Brian Daniels's Form 4/A - Amendment filing for Cabaletta Bio, Inc. (CABA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jun 2021, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CABA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: -22,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,000
Exercise price: $11.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Brian Daniels is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

This option shall vest in accordance with the following schedule: (1) 25% of the shares subject to the option shall vest on June 24, 2022 and (2) the remaining 75% of the shares subject to the option shall vest in equal quarterly installments over the next 3 years, subject to the Reporting Person's continued service relationship with the Issuer.

SEC remarks

This Form 4 is being filed to amend the vesting terms of this grant. The amended vesting term is listed in Footnote #1.